# Regulatory Compliance - Neurology Domain

## Overview

Regulatory compliance encompasses the legal, governance, and ethical requirements that shape the neurology domain model design. Healthcare is one of the most heavily regulated industries, and neurology systems must comply with regulations governing patient privacy, medical device safety, clinical research, and data management.

In Domain-Driven Design, regulatory requirements are not treated as external constraints bolted onto the model. Instead, they are embedded within the domain model itself, expressed through aggregate invariants, value object validations, and domain event policies that enforce compliance as part of normal domain operations.

## HIPAA (Health Insurance Portability and Accountability Act)

### Privacy Rule

The HIPAA Privacy Rule governs the use and disclosure of Protected Health Information (PHI). In the neurology domain, PHI includes:

- Patient demographics and identifiers.
- Neurological examination findings and diagnoses.
- Neuroimaging studies and reports.
- Genetic testing results.
- Seizure diaries and medication records.
- Rehabilitation functional assessments.

Impact on the domain model:
- Patient entities carry minimum necessary identifiers; full demographics are accessed through controlled interfaces.
- Domain events carry only the minimum data necessary for consumers to act. An ExaminationCompleted event includes summary findings, not the complete examination record.
- Access to sensitive data (genetic results, psychiatric diagnoses, substance use history) is subject to additional restrictions modeled as access control policies within the domain.

### Security Rule

The HIPAA Security Rule requires administrative, physical, and technical safeguards for electronic PHI (ePHI).

Impact on the domain model:
- Audit trail: every domain event is persisted in an event store, providing a complete audit trail of all data access and modifications.
- Data integrity: value object immutability ensures that clinical data cannot be silently modified.
- Authentication and authorization: domain services validate that the requesting user has appropriate permissions for the requested operation.

### Breach Notification Rule

Organizations must notify affected individuals, HHS, and potentially the media in the event of a PHI breach.

Impact on the domain model:
- Data breach detection capabilities are modeled as domain events (UnauthorizedAccessDetected, DataBreachSuspected).
- Breach assessment workflows are supported by the domain model.

## FDA Medical Device Regulations

### Software as a Medical Device (SaMD)

Components of the neurology domain may qualify as Software as a Medical Device under FDA regulations:

- Clinical decision support systems that recommend seizure classifications, AED selection, or surgical candidacy.
- Imaging interpretation algorithms that identify abnormalities on MRI or EEG.
- Disease progression prediction services that forecast clinical outcomes.

Impact on the domain model:
- Domain services that provide clinical decision support must clearly distinguish between "informational" output (not SaMD) and "diagnostic/therapeutic" recommendations (potentially SaMD).
- Risk classification (Class I, II, III) of domain components affects testing and documentation requirements.
- Design controls (21 CFR 820) may apply to domain model components classified as SaMD.

### Implantable Device Regulations

VNS and RNS devices in the Epilepsy Management Context are FDA-regulated Class III medical devices:

- Device tracking requirements: unique device identifiers (UDI), implant dates, model numbers.
- Adverse event reporting: mandatory reporting of device malfunctions and adverse events to FDA (MedWatch).
- Post-market surveillance: ongoing monitoring of device performance and safety.

Impact on the domain model:
- Device entities in the Epilepsy Management Context carry FDA-required tracking information.
- Device-related adverse events are modeled as domain events with mandatory reporting workflows.
- Programming parameter changes are logged with timestamps and clinical justification.

## Clinical Research Regulations

### FDA 21 CFR Part 11

Electronic records and electronic signatures for clinical trial data:

- Clinical trial data within the Neurodegenerative Disease Context must comply with Part 11 requirements for electronic records.
- Audit trails must capture who created, modified, or deleted data, when, and why.
- Electronic signatures must be legally binding and tamper-resistant.

Impact on the domain model:
- ClinicalTrialEnrollment entities include Part 11-compliant audit metadata.
- Data modifications within clinical trial contexts are recorded as immutable domain events.

### Good Clinical Practice (GCP / ICH E6)

International guidelines for clinical trial conduct:

- Source data verification: domain model data used in clinical trials must be traceable to its source.
- Data integrity: clinical trial data must be attributable, legible, contemporaneous, original, and accurate (ALCOA).
- Informed consent tracking: modeled as a prerequisite invariant for clinical trial enrollment.

Impact on the domain model:
- ClinicalTrialEnrollment aggregates enforce informed consent as a prerequisite invariant.
- Source data identifiers link domain data to original clinical records.

### IRB/Ethics Committee Oversight

Clinical research within the domain requires Institutional Review Board (IRB) approval:

- Protocol approval status is modeled as a value object within clinical trial aggregates.
- Enrollment cannot proceed without active IRB approval (enforced as an aggregate invariant).
- Amendments to research protocols are tracked as domain events.

## State and International Regulations

### State Medical Privacy Laws

Some states have regulations stricter than HIPAA:

- Genetic testing privacy: many states have additional protections for genetic information that affect the Neuromuscular Disorders Context.
- Mental health record protections: additional restrictions on psychiatric and psychological data.
- Mandatory reporting: state-specific requirements for reporting certain neurological conditions (e.g., seizures and driving).

Impact on the domain model:
- Jurisdiction-specific privacy rules are modeled as configurable policies rather than hard-coded invariants.
- Seizure reporting requirements in the Epilepsy Management Context include jurisdiction-specific driving notification rules.

### GDPR (General Data Protection Regulation)

For international neurology systems handling EU patient data:

- Right to access: patients can request their neurological data.
- Right to erasure: patients can request deletion of their data, subject to clinical record retention requirements.
- Data portability: patients can request their data in a machine-readable format (FHIR export).
- Data protection impact assessments for high-risk processing (genetic data, health data).

### GINA (Genetic Information Nondiscrimination Act)

Protections for genetic information used in the Neuromuscular Disorders Context:

- Genetic test results cannot be used for employment or health insurance discrimination.
- Genetic information requires additional access controls beyond standard PHI protections.

## Compliance Documentation

The domain model supports regulatory compliance through:

- Immutable event stores providing audit trails.
- Value object self-validation enforcing data quality rules.
- Aggregate invariants enforcing clinical and regulatory business rules.
- Domain events enabling real-time compliance monitoring and alerting.
- Configurable policy objects supporting jurisdiction-specific regulatory requirements.

## References

- Evans, Eric. *Domain-Driven Design: Tackling Complexity in the Heart of Software*. Addison-Wesley, 2003.
- Vernon, Vaughn. *Implementing Domain-Driven Design*. Addison-Wesley, 2013.
- Khononov, Vlad. *Learning Domain-Driven Design*. O'Reilly Media, 2021.
- U.S. Department of Health and Human Services. HIPAA Privacy, Security, and Breach Notification Rules.
- U.S. Food and Drug Administration. 21 CFR Part 820 (Quality System Regulation).
- U.S. Food and Drug Administration. Guidance on Software as a Medical Device (SaMD).
- International Council for Harmonisation (ICH). E6(R2) Good Clinical Practice Guidelines.
